Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 282-293

  Peng, Yi Hui ^a   Ueng, Shau Hua ^a   Tseng, Chen Tso ^a   Hung, Ming Shiu ^a   Song, Jen Shin ^a   Wu, Jian Sung ^a   Liao, Fang Yu ^a   Fan, Yu Shiou ^a   Wu, Mine Hsine ^a   Hsiao, Wen Chi ^a   Hsueh, Ching Cheng ^a   Lin, Shu Yu ^a   Cheng, Chia Yi ^a   Tu, Chih Hsiang ^a   Lee, Lung Chun ^a   Cheng, Ming Fu ^a   Shia, Kak Shan ^a   Shih, Chuan ^a   Wu, Su Ying ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXANE DERIVATIVE; HEME; IMIDAZOLE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; ISOINDOLE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; IMIDAZOLES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84955309574     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01390     Document Type: Article

References (50)

1. Lob, S.; Konigsrainer, A.; Rammensee, H. G.; Opelz, G.; Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 2009, 9, 445-452 10.1038/nrc2639
2. Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance J. Clin. Invest. 2007, 117, 1147-1154 10.1172/JCI31178
3. Hwu, P.; Du, M. X.; Lapointe, R.; Do, M.; Taylor, M. W.; Young, H. A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation J. Immunol. 2000, 164, 3596-3599 10.4049/jimmunol.164.7.3596
4. Curti, A.; Trabanelli, S.; Salvestrini, V.; Baccarani, M.; Lemoli, R. M. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood 2009, 113, 2394-2401 10.1182/blood-2008-07-144485
5. Smith, C.; Chang, M. Y.; Parker, K. H.; Beury, D. W.; DuHadaway, J. B.; Flick, H. E.; Boulden, J.; Sutanto-Ward, E.; Soler, A. P.; Laury-Kleintop, L. D.; Mandik-Nayak, L.; Metz, R.; Ostrand-Rosenberg, S.; Prendergast, G. C.; Muller, A. J. IDO is a nodal pathogenic driver of lung cancer and metastasis development Cancer Discovery 2012, 2, 722-735 10.1158/2159-8290.CD-12-0014
6. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 2009, 52, 7364-7367 10.1021/jm900518f
7. Koblish, H. K.; Hansbury, M. J.; Bowman, K. J.; Yang, G.; Neilan, C. L.; Haley, P. J.; Burn, T. C.; Waeltz, P.; Sparks, R. B.; Yue, E. W.; Combs, A. P.; Scherle, P. A.; Vaddi, K.; Fridman, J. S. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors Mol. Cancer Ther. 2010, 9, 489-498 10.1158/1535-7163.MCT-09-0628
8. Mautino, M. R.; Jaipuri, F. A.; Waldo, J.; Kumar, S.; Adams, J.; Van Allen, C.; Marcinowicz-Flick, A.; Munn, D.; Vahanian, N.; Link, C. J. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy Cancer Res. 2013, 73, 491 10.1158/1538-7445.AM2013-491
9. Rohrig, U. F.; Majjigapu, S. R.; Vogel, P.; Zoete, V.; Michielin, O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors J. Med. Chem. 2015, 10.1021/acs.jmedchem.5b00326
10. Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L. P.; Borges, L.; McCarter, J. D.; Sutherland, C. L. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors Biochim. Biophys. Acta, Proteins Proteomics 2011, 1814, 1947-1954 10.1016/j.bbapap.2011.07.023
11. Balog, J. A.; Huang, A.; Chen, B.; Chen, L.; Shan, W. IDO inhibitors. Patent WO2014/150646, 2014.
12. Sheridan, C. IDO inhibitors move center stage in immuno-oncology Nat. Biotechnol. 2015, 33, 321-322 10.1038/nbt0415-321
13. Banerjee, M.; Middya, S.; Shrivastava, R.; Raina, S.; Surya, A.; Yadav, V. K.; Kapoor, K. K. Aminonitriles as kynurenine pathway inhibitors. Patent WO2014/141110, 2014.
14. Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2611-2616 10.1073/pnas.0508996103
15. Tojo, S.; Kohno, T.; Tanaka, T.; Kamioka, S.; Ota, Y.; Ishii, T.; Kamimoto, K.; Asano, S.; Isobe, Y. Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors ACS Med. Chem. Lett. 2014, 5, 1119-1123 10.1021/ml500247w
16. Sono, M.; Cady, S. G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands Biochemistry 1989, 28, 5392-5399 10.1021/bi00439a012
17. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase J. Med. Chem. 2008, 51, 4968-4977 10.1021/jm800512z
18. Dounay, A. B.; Tuttle, J. B.; Verhoest, P. R. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway J. Med. Chem. 2015, 58, 8762-8782 10.1021/acs.jmedchem.5b00461
19. Dawson, J. H.; Andersson, L. A.; Sono, M. Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme J. Biol. Chem. 1982, 257, 3606-3617
20. Littlejohn, T. K.; Takikawa, O.; Skylas, D.; Jamie, J. F.; Walker, M. J.; Truscott, R. J. Expression and purification of recombinant human indoleamine 2, 3-dioxygenase Protein Expression Purif. 2000, 19, 22-29 10.1006/prep.2000.1214
21. Rohrig, U. F.; Majjigapu, S. R.; Grosdidier, A.; Bron, S.; Stroobant, V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition J. Med. Chem. 2012, 55, 5270-5290 10.1021/jm300260v
22. Schenkman, J. B.; Sligar, S. G.; Cinti, D. L. Substrate interaction with cytochrome P-450 Pharmacol. Ther. 1981, 12, 43-71 10.1016/0163-7258(81)90075-9
23. Brown, D. G.; Flocco, M. M. Useful crystallographic terminology when utilising crystal structures. In Structure-Based Drug Discovery: An Overview; Hubbard, R. E., Ed.; Royal Society of Chemistry: Cambridge, U.K., 2006; p 38.
24. Wlodawer, A.; Minor, W.; Dauter, Z.; Jaskolski, M. Protein crystallography for aspiring crystallographers or how to avoid pitfalls and traps in macromolecular structure determination FEBS J. 2013, 280, 5705-5736 10.1111/febs.12495
25. Smart, O. S.; Bricogne, G. Achieving High Quality Ligand Chemistry in Protein-Ligand Crystal Structures for Drug Design. In Multifaceted Roles of Crystallography in Modern Drug Discovery; Scapin, G.; Patel, D.; Arnold, E., Eds.; Springer: Dordrecht, The Netherlands, 2015; pp 165-181, DOI: 10.1007/978-94-017-9719-1-13.
26. Smart, O. S.; Womack, T. O.; Flensburg, C.; Keller, P.; Paciorek, W.; Sharff, A.; Vonrhein, C.; Bricogne, G. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012, 68, 368-380 10.1107/S0907444911056058
27. Das, A.; Zhao, J.; Schatz, G. C.; Sligar, S. G.; Van Duyne, R. P. Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy Anal. Chem. 2009, 81, 3754-3759 10.1021/ac802612z
28. Martin, S. F. Preorganization in biological systems: Are conformational constraints worth the energy? Pure Appl. Chem. 2007, 79, 193-200 10.1351/pac200779020193
29. Harter, W. G.; Albrect, H.; Brady, K.; Caprathe, B.; Dunbar, J.; Gilmore, J.; Hays, S.; Kostlan, C. R.; Lunney, B.; Walker, N. The design and synthesis of sulfonamides as caspase-1 inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 809-812 10.1016/j.bmcl.2003.10.065
30. Mautino, M.; Kumar, S.; Waldo, J.; Jaipuri, F.; Kesharwani, T.; Zhang, X. Fused imidazole derivatives useful as IDO inhibitors. Patent WO 2012/142237, 2012.
31. Hintermann, L.; Dang, T. T.; Labonne, A.; Kribber, T.; Xiao, L.; Naumov, P. The AZARYPHOS family of ligands for ambifunctional catalysis: syntheses and use in ruthenium-catalyzed anti-Markovnikov hydration of terminal alkynes Chem.-Eur. J. 2009, 15, 7167-7179 10.1002/chem.200900563
32. Kumar, S.; Waldo, J.; Jaipuri, F.; Mautino, M. Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization. Patent WO2014/159248, 2014.
33. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601-2611 10.1021/jm100087s
34. Nomura, M.; Kinoshita, S.; Satoh, H.; Maeda, T.; Murakami, K.; Tsunoda, M.; Miyachi, H.; Awano, K. (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents Bioorg. Med. Chem. Lett. 1999, 9, 533-538 10.1016/S0960-894X(99)00039-6
35. Van Zandt, M. C.; Sibley, E. O.; McCann, E. E.; Combs, K. J.; Flam, B.; Sawicki, D. R.; Sabetta, A.; Carrington, A.; Sredy, J.; Howard, E.; Mitschler, A.; Podjarny, A. D. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications Bioorg. Med. Chem. 2004, 12, 5661-5675 10.1016/j.bmc.2004.07.062
36. Furet, P.; Bold, G.; Hofmann, F.; Manley, P.; Meyer, T.; Altmann, K. H. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching Bioorg. Med. Chem. Lett. 2003, 13, 2967-2971 10.1016/S0960-894X(03)00626-7
37. Ashwood, V. A.; Field, M. J.; Horwell, D. C.; Julien-Larose, C.; Lewthwaite, R. A.; McCleary, S.; Pritchard, M. C.; Raphy, J.; Singh, L. Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist J. Med. Chem. 2001, 44, 2276-2285 10.1021/jm010825z
38. Sasaki, S.; Cho, N.; Nara, Y.; Harada, M.; Endo, S.; Suzuki, N.; Furuya, S.; Fujino, M. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor J. Med. Chem. 2003, 46, 113-124 10.1021/jm020180i
39. Rezai, T.; Bock, J. E.; Zhou, M. V.; Kalyanaraman, C.; Lokey, R. S.; Jacobson, M. P. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides J. Am. Chem. Soc. 2006, 128, 14073-14080 10.1021/ja063076p
40. Over, B.; McCarren, P.; Artursson, P.; Foley, M.; Giordanetto, F.; Gronberg, G.; Hilgendorf, C.; Lee, M. D. t.; Matsson, P.; Muncipinto, G.; Pellisson, M.; Perry, M. W.; Svensson, R.; Duvall, J. R.; Kihlberg, J. Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties J. Med. Chem. 2014, 57, 2746-2754 10.1021/jm500059t
41. Abraham, M. H.; Ibrahim, A.; Zissimos, A. M.; Zhao, Y. H.; Comer, J.; Reynolds, D. P. Application of hydrogen bonding calculations in property based drug design Drug Discovery Today 2002, 7, 1056-1063 10.1016/S1359-6446(02)02478-9
42. Wijtmans, M.; Celanire, S.; Snip, E.; Gillard, M. R.; Gelens, E.; Collart, P. P.; Venhuis, B. J.; Christophe, B.; Hulscher, S.; van der Goot, H.; Lebon, F.; Timmerman, H.; Bakker, R. A.; Lallemand, B. I.; Leurs, R.; Talaga, P. E.; de Esch, I. J. 4-Benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists J. Med. Chem. 2008, 51, 2944-2953 10.1021/jm7014149
43. Cheng, M. F.; Hung, M. S.; Song, J. S.; Lin, S. Y.; Liao, F. Y.; Wu, M. H.; Hsiao, W.; Hsieh, C. L.; Wu, J. S.; Chao, Y. S.; Shih, C.; Wu, S. Y.; Ueng, S. H. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 3403-3406 10.1016/j.bmcl.2014.05.084
44. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025 10.1107/S0021889897006766
45. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763 10.1107/S0907444994003112
46. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255
47. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119 10.1107/S0108767390010224
48. Afonine, P. V.; Grosse-Kunstleve, R. W.; Echols, N.; Headd, J. J.; Moriarty, N. W.; Mustyakimov, M.; Terwilliger, T. C.; Urzhumtsev, A.; Zwart, P. H.; Adams, P. D. Towards automated crystallographic structure refinement with phenix.refine Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012, 68, 352-367 10.1107/S0907444912001308
49. Joosten, R. P.; Salzemann, J.; Bloch, V.; Stockinger, H.; Berglund, A.-C.; Blanchet, C.; Bongcam-Rudloff, E.; Combet, C.; Da Costa, A. L.; Deleage, G.; Diarena, M.; Fabbretti, R.; Fettahi, G.; Flegel, V.; Gisel, A.; Kasam, V.; Kervinen, T.; Korpelainen, E.; Mattila, K.; Pagni, M.; Reichstadt, M.; Breton, V.; Tickle, I. J.; Vriend, G. PDB-REDO: automated re-refinement of X-ray structure models in the PDB J. Appl. Crystallogr. 2009, 42, 376-384 10.1107/S0021889809008784
50. Chen, V. B.; Arendall, W. B., 3rd; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 12-21 10.1107/S0907444909042073